SSTR2 and neoplasm: Similarly, Watson et al. revealed that only growing endothelial cells express SSTR2; therefore, they suggested that since an angiogenic response is required for tumours to grow more than 2 mm in diameter, SSTR2 antagonists could be a potential therapeutic approach for tumours larger than 2 mm [29].